Anti-Complement C5 Antibody, clone SIM 225-3.2.1

Quality Control Testing

Evaluated by Western Blotting with Human Complement C5 glycoprotein (non-reduced).

Western Blotting Analysis: A 1:5,000 dilution of this antibody detected non-reduced Human Complement C5.

Tested Applications

Western Blotting Analysis: A representative lot detected Complement C5 in Western Blotting applications (Monedero, M., et al. (2019). Comp Immunol Microbiol Infect Dis. 62:7-12).

Flow Cytometry Analysis: A representative lot detected Complement C5 in Flow Cytometry applications (Monedero, M., et al. (2019). Comp Immunol Microbiol Infect Dis. 62:7-12).

ELISA Analysis: A representative lot detected Complement C5 in applications (Monedero, M., et al. (2019). Comp Immunol Microbiol Infect Dis. 62:7-12).

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Clone SIM 225-3.2.1 is a mouse monoclonal antibody that detects Complement 5.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Complement C5 (UniProt: P01031; also known as C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4) is encoded by the C5 (also known as CPAMD4) gene (Gene ID: 727) in human. The complement system provides innate defense against microbial infection and is a complement to antibody-mediated immunity. It consists of about thirty-five interacting plasma and membrane associated proteins. Activation of the complement system is achieved through three major independent, but overlapping, pathways: the classical pathway, which is activated by certain isotypes of antibodies bound to antigens (immune complexes); the alternative pathway, which is activated on microbial cell surfaces in the absence of antibody; and the lectin pathway, which is activated by a plasma lectin (mannose binding lectin) that binds to mannose residues on microbes. The human C5 complement component is a glycoprotein that is synthesized with a signal peptide (aa 1-18), which is subsequently cleaved off to produce the mature protein that can further cleave into four chains: Complement C5 beta chain (aa 19-673); Complement C5 alpha chain (aa 678-1676); C5a anaphylatoxin (aa 678-751); and Complement C5 alpha′ chain (aa752-1676). The C5 convertase activates C5 by cleaving the alpha chain, releasing C5a anaphylatoxin and generating C5b. C5a serves as an inflammatory mediator that can activate a variety of cells through G-protein-linked receptors. The C5b fragment combines with C6, C7, C8, and C9 to form lytic C5b-9 complement membrane attack complex (MAC) that is responsible for the membrane lytic events associated with complement activation. Mutations in C5 gene are known to cause complement component 5 deficiency (C5D), a rare defect of the complement classical pathway that leads to susceptibility to severe recurrent infections. (Ref.: Monedero, M., et al. (2019). Comp. Immunol. Microbiol. Infect. Dis. 62; 7-12; Horiuchi, T., and Tsukamoto, H. (2016). Inflamm. Regen. 36; Article 11).

Complement C5 from human serum.

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Purified mouse monoclonal antibody IgG1 in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

0.5 mg/mL. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommended storage: +2°C to +8°C